LEXINGTON, Mass., Sept. 17,
2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib
(CA-4948), an orally available, small molecule IRAK4 inhibitor,
today announced that James Dentzer,
President and Chief Executive Officer of Curis, will participate in
a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare
Conference later today at 4:15 PM ET.
Details for the webcast can be found using the Cantor webcast
link.
The webcast will be also available on the Curis website
at www.curis.com in the 'Investors' section.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study (CA-4948-101) in patients with
relapsed/refractory primary central nervous system lymphoma (PCNSL)
in combination with the BTK inhibitor ibrutinib, as a monotherapy
in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients
with relapsed/refractory acute myeloid leukemia (AML) and
relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with
either a FLT3 mutation or a splicing factor mutation (U2AF1 or
SF3B2), and as a frontline combination therapy with azacitidine and
venetoclax in patents with AML (CA-4948-104). Emavusertib has
received Orphan Drug Designation from the U.S. Food and Drug
Administration for the treatment of AML and MDS and from the
European Commission for the treatment of PCNSL. Curis, through its
2015 collaboration with Aurigene, has the exclusive license to
emavusertib (CA-4948). Curis licensed its rights to Erivedge® to
Genentech, a member of the Roche Group, under which they are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website at
www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-participate-at-the-upcoming-2024-cantor-fitzgerald-global-healthcare-conference-302249626.html
SOURCE Curis, Inc.